Bhagirathbhai R. Dholaria, MBBS, discusses updated findings from the TRIMM-2 trial of talquetamab and daratumumab for the treatment of relapsed/refractory multiple myeloma.
Systemic Review/Meta-Analysis From ASH 2024 Examining the AQUILA Trial Presented at ASH 2024 Clinical Insights: Starting with a Patient Case 1: 74yo 74-Year-Old Patient With NDMM Transplant- Ineligible NDMM Identification, Evaluation, and Management of High-Risk Disease in Early R/R MMRelat...